LivaNova PLC (LIVN) – What Are Analysts Saying About This Stock?

Shares of LivaNova PLC (NASDAQ:LIVN) have been given an average rating of “Moderate Buy” by the eleven brokerages that are covering the stock, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $87.75.

LIVN has been the topic of several recent analyst reports. Weiss Ratings raised shares of LivaNova from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, August 18th. Barclays raised shares of LivaNova to a “strong-buy” rating in a report on Wednesday, October 7th. Piper Sandler reaffirmed an “overweight” rating and set a $90.00 price target (up from $87.00) on shares of LivaNova in a report on Wednesday, September 2nd. Mizuho increased their price target on shares of LivaNova from $90.00 to $95.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. Finally, Stifel Nicolaus set a $85.00 price objective on shares of LivaNova in a research note on Wednesday, August 5th.

Insider Activity at LivaNova

In other LivaNova news, Director Brooke Story sold 2,300 shares of the firm’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $81.42, for a total value of $187,266.00. Following the sale, the director owned 7,488 shares of the company’s stock, valued at approximately $609,672.96. This trade represents a 23.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Francesco Bianchi sold 3,500 shares of LivaNova stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $78.01, for a total value of $273,035.00. Following the completion of the transaction, the director owned 4,434 shares in the company, valued at approximately $345,896.34. The trade was a 44.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 7,450 shares of company stock valued at $591,839. Company insiders own 0.35% of the company’s stock.

Institutional Trading of LivaNova

Institutional investors and hedge funds have recently modified their holdings of the business. Squarepoint Ops LLC bought a new position in LivaNova in the second quarter valued at about $1,418,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in LivaNova during the second quarter worth about $4,053,000. Maverick Capital Ltd. acquired a new position in LivaNova during the first quarter worth about $956,000. Avidian Wealth Enterprises LLC acquired a new position in LivaNova during the third quarter worth about $752,000. Finally, Renaissance Technologies LLC lifted its holdings in shares of LivaNova by 15.7% in the first quarter. Renaissance Technologies LLC now owns 183,000 shares of the company’s stock worth $11,631,000 after acquiring an additional 24,900 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

LivaNova Stock Down 1.2%

Shares of NASDAQ LIVN opened at $76.37 on Friday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.45. LivaNova has a 52 week low of $48.82 and a 52 week high of $85.76. The stock has a market capitalization of $4.21 billion, a P/E ratio of 21.52 and a beta of 0.87. The stock’s fifty day moving average is $78.50 and its 200 day moving average is $75.29.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings results on Thursday, August 6th. The company reported $1.26 EPS for the quarter, beating analysts’ consensus estimates of $1.09 by $0.17. LivaNova had a return on equity of 16.35% and a net margin of 12.82%. The business had revenue of $390.59 million during the quarter, compared to the consensus estimate of $380.50 million. During the same quarter in the previous year, the firm earned $1.05 earnings per share. LivaNova’s revenue for the quarter was up 10.8% compared to the same quarter last year. Sell-side analysts forecast that LivaNova will post 3.78 earnings per share for the current fiscal year.

About LivaNova

LivaNova PLC (NASDAQ: LIVN) is a medical device company that develops and markets technologies for the treatment of cardiovascular and neurological conditions. The company’s principal businesses are organized around its Cardiopulmonary and Neuromodulation segments.

Its cardiopulmonary portfolio includes heart-lung machines, oxygenators, perfusion systems and other equipment used during cardiopulmonary bypass procedures, as well as technologies designed to support cardiac surgery and related clinical applications.